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Summary 
One of the key knowledge gaps blocking development of effective therapeutics for Alzheimer’s disease 
(AD) is the lack of understanding of how amyloid beta peptide (Aß) and pathological forms of the tau 
protein cooperate in causing disease phenotypes. Within a mouse tau deficient background, we probed 
the molecular, cellular and behavioural disruption triggered by wild-type human tau’s influence on human 
Aß-induced pathology. We find that Aß and tau work cooperatively to cause a hyperactivity behavioural 
phenotype and to cause downregulation of transcription of genes involved in synaptic function. In both 
our mouse model and in human post-mortem tissue, we observe accumulation of pathological tau in 
synapses, supporting the potential importance of synaptic tau. Importantly, tau reduction in the mice 
initiated after behavioural deficits emerge was found to correct behavioural deficits, reduce synaptic tau 
levels, and substantially reverse transcriptional perturbations, suggesting that lowering synaptic tau levels 
may be beneficial in AD. 
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Introduction 
Over 50 million people are living with dementia today, and approximately $800 billion per year is spent 
worldwide on their health and social care (Prince et al., 2015). Alzheimer’s disease (AD) is the most 
common cause of dementia, and current treatments are only minimally effective and do not prevent brain 
degeneration or cognitive decline. AD is defined pathologically by the accumulation of amyloid plaques 
made of aggregated amyloid beta (Aß), neurofibrillary tangles which are intraneuronal deposits of 
hyperphosphorylated tau protein, and brain atrophy due to neuron and synapse loss. The predominating 
hypothesis in the AD field, the amyloid cascade hypothesis, posits that changes in Aß initiate a cascade of 
events including pathological changes in tau (Hardy and Higgins, 1992, Hyman, 2011). Genetic studies 
indicate that changes in the innate immune system are also important in conferring disease risk (De 
Strooper and Karran, 2016, Henstridge et al., 2019). How Aß, glial/innate immune changes, and tau 
interact to cause neurodegeneration remains a key knowledge gap in the field.  
Synapses are an important target to study in AD as synapse degeneration is the strongest correlate of 
cognitive decline (Terry et al., 1991) and synapses are important early in disease pathogenesis and the 
spread of pathological proteins through the brain (Spires-Jones and Hyman, 2014, Spires-Jones et al., 
2017, DeVos et al., 2018b). Substantial amounts of evidence implicate oligomeric Aß in synapse 
degeneration in model systems and in human post-mortem tissue (Li et al., 2009, Mucke and Selkoe, 2012, 
Klein, 2013, Spires et al., 2005, Spires-Jones et al., 2007, Spires-Jones et al., 2009, Koffie et al., 2009, Koffie 
et al., 2012, Jackson et al., 2019). Some of the toxic effects of Aß appear to be mediated by cascades which 
are normally involved in the innate immune system including complement and TREM2 (Hong et al., 2016, 
Jay et al., 2017, Yeh et al., 2016, Henstridge et al., 2019). Pathological forms of tau are also sufficient to 
induce synapse loss and circuit dysfunction in models of tauopathy (Kopeikina et al., 2012, Menkes-Caspi 
et al., 2015, Crimins et al., 2013, Fox et al., 2011, Hoover et al., 2010, Zhou et al., 2017, Busche et al., 
2019). 
 
There is accumulating evidence that Aß and tau may act synergistically to cause synaptic dysfunction, 
neurofibrillary tangle mediated neuron loss, and behavioural deficits (Ittner et al., 2010, Vargas-Caballero 
et al., 2017, Roberson et al., 2011, Shipton et al., 2011, Jackson et al., 2016, DeVos et al., 2018a). However, 
much of the previous work was confounded by the complex differences between mouse and human tau 
and the inability to control tau expression. Further, many of the previous studies examining interactions 
between Aß and tau used tau mutations associated with frontotemporal dementia to drive neurofibrillary 
  3 
pathology. While these are excellent models for studying tau pathology, they do not accurately 
recapitulate the state in early AD in which soluble, wild-type human tau is likely interacting with rising 
levels of oligomeric Aß to confer synaptic toxicity. To overcome these limitations, and test the hypothesis 
that Aß and tau act cooperatively to cause behavioural and transcriptional deficits, we designed a model 
lacking endogenous mouse tau (MAPTnull) and expressing both the APP/PS1 transgene, which causes 
well-characterized plaque-associated synapse loss (Jankowsky et al., 2004, Koffie et al., 2009), and the 
rTg21221 line which reversibly expresses wild-type human tau under the control of an inducible promotor 
(Hoover et al., 2010).  This MAPTnull+APP/PS1+rTg21221 AD model (APP/PS1+Tau) allows control over 
tau levels by suppression of tau transgene expression. We examined the behaviour, pathology, synapse 
degeneration, transcriptional changes and accumulation of Aβ and tau at synapses in the APP/PS1+Tau 
model and compared these data to observations of synapses in human post-mortem brain using the high-
resolution array tomography imaging technique (Kay et al., 2013). 
 
Results 
APP/PS1+Tau mice develop age-related behavioural and transcriptional phenotypes  
To understand the effects of combining plaque pathology with human tau expression, we examined 
pathology and behaviour during ageing in APP/PS1+Tau mice and 3 littermate control genotypes: control 
(MAPTnull), APP/PS1 only (MAPTnullxAPP/PS1), and human tau only (MAPTnullxrTg21221, Fig. 1A,B). 
Pathological and behavioural data for each mouse are found in table S1. APP/PS1+Tau mice develop 
progressive amyloid plaque pathology in the absence of tau pathology (Fig. 1C-E). Similar to previous data 
for the rTg21221 line (Hoover et al., 2010), APP/PS1+Tau mice over express human tau ~12-fold compared 
to endogenous mouse tau levels seen in wild-type mice by qPCR (human and mouse tau normalized to 
GAPDH, n=5 per group, data not shown). In both genotypes of mice expressing the APP/PS1 transgene, 
amyloid plaques begin to appear in cortex and hippocampus by 6 months of age and plaque burden 
increases with age. Plaque deposition differs between APP/PS1 mice and APP/PS1+Tau mice with 
surprisingly lower plaque in APP/PS1+Tau mice (Fig. 1D). Although human tau mRNA and protein could be 
detected in the two genotypes expressing both the human tau responder gene and the CkTta activator 
transgene, no tau pathology was observed at any age with staining for phosphorylated or misfolded tau 
epitopes (AT8, PHF1, Alz50) or with histological staining of fibrils with thioflavin S (Fig. 1E). The efficacy of 
tau staining was confirmed using rTg4510 mouse brain sections (which express a form of tau associated 
with frontotemporal dementia and contain tangle pathology), verifying that all tau antibodies stained 
neurofibrillary tangles. APP/PS1+Tau mice did not exhibit age-related atrophy in cortex (Fig. 1F) or 
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hippocampus (Fig. S1). 
In addition to plaque accumulation and human tau expression, APP/PS1+Tau mice exhibit an age-related 
hyperactivity phenotype (Fig. 2A,B). After 3 days of habituation, mice were placed in an open field and 
the total distance travelled over 10 minutes was recorded. Two-way ANOVA reveals a significant effect of 
genotype (F[3,202]=314.76, p<0.0001) with APP/PS1+Tau mice travelling further than controls at 10.5 and 
14.5 months of age (Tukey’s multiple comparisons test p<=0.01 for all comparisons of APP/PS1+Tau vs 
other 3 genotypes at 10.5 and 14.5 months). There was no effect of age when all mice were considered 
together (F[4,202]=1.61, p=0.17) but there was a significant interaction between age and genotype 
(F[12,202]=2.30, p=0.01) due to the APP/PS1+Tau mice travelling further in the open field than the other 
genotypes as they age. The hyperactivity phenotype is not different in male vs female APP/PS1+Tau mice 
(Fig. S2).  Neither is the hyperactivity driven by tau protein levels which do not differ between 
APP/PS1+Tau mice and tau mice as measured by ELISA in cortical homogenates from 14.5 month old mice 
(mean 11.0 ng/mg total protein in tau mice, 9.5 ng/mg total protein in APP/PS1+Tau mice n=5 per group, 
p>0.05 Tukey’s post hoc test). Group sizes and sex of mice in behavioural studies are shown in figures and 
in table S1. 
 
To examine transcriptional changes in APP/PS1+Tau mice, we performed unbiased RNA-seq on brain 
homogenates at 14.5 months of age (RNAseq data found in table S2). When compared to control mice, 
APP/PS1 had 81 transcripts that changed more than 2 fold and had an adjusted p value of less than 0.05 
(Fig. 2C). Tau mice were very similar to controls with only 6 transcripts significantly changing more than 
2 fold, one of which is Mapt which is expected due to tau overexpression (Fig. 2D).  In contrast,  
APP/PS1+Tau mice had 1531 transcripts which were significantly altered compared to MAPTnull control 
mice and 127 of these were changed by greater than 2 fold (Fig. 2E). Thus, the gene changes in 
APP/PS1+Tau mice compared to control are much larger than either APP/PS1 mice or Tau mice, 
indicating cooperation between A and tau in causing transcriptional dysregulation. Ingenuity Pathway 
Analysis indicates that many of the upregulated genes in APP/PS1+Tau mice are typically expressed in 
glia (summary pathways of interest based on the literature shown in Fig. 2G, full pathway analyses in 
table S3). This includes increased expression of Trem2, Gfap, Cd68, C1q, and H2-Eb1 and significant 
increases in canonical pathways implicated in neuroinflammation (Fig 2G). Many of the downregulated 
genes in APP/PS1+Tau mice are involved in canonical pathways involved in synaptic function including 
glutamate receptor signalling and calcium signalling (AMPA and NMDA receptor subunits, Gria2, Gria3, 
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Gria4, Grin2a, Homer2 and Camk2b are downregulated, Fig 2G). One synaptic transcript that was 
significantly upregulated is cellular prion protein (Prnp), which is very interesting since it is a known 
synaptic binding partner of Aß (Um et al., 2012).  
Upregulation of genes in APP/PS1+Tau mice appears to be largely driven by Aß and tau independently 
without an additive effect since the fold induction of upregulated genes is very similar in APP/PS1+Tau 
mice to the maximum fold induction in either APP/PS1 or Tau mice. Most of the upregulated transcripts 
in APP/PS1+Tau mice correlate strongly with the maximum fold change in APP/PS1 mice (Fig. 2F), and 
most upregulated pathways in APP/PS1+Tau mice are upregulated to a similar extent in APP/PS1 mice 
(Fig.2G). There are a few pathways upregulated more in APP/PS1+Tau mice than in APP/PS1 or Tau mice 
including the complement system (Fig. 2G). In contrast to the relatively few changes seen in upregulated 
genes, Aß and tau act additively in downregulating gene expression. The fold downregulation compared 
to controls in APP/PS1+Tau mice is more than the maximum change in either APP/PS1 mice or Tau mice 
(Fig. 2F).  Interestingly, pathway analysis reveals the glutamate receptor signalling pathway is significantly 
decreased in APP/PS1+Tau mice compared to controls and unaffected in either parent line (Fig 2G). One 
potential mechanistic link between upregulated inflammatory pathways and synaptic dysfunction and 
decreases in synaptic gene expression is the phagocytosis of synaptic proteins by microglia. The 
complement system has been previously shown to be involved in phagocytosis of synapses in plaque and 
tangle bearing models separately (Dejanovic et al., 2018, Hong et al., 2016, Litvinchuk et al., 2018, Shi et 
al., 2017). In addition to upregulation of genes involved in the complement system and downregulation 
of genes involved in synaptic function in APP/PS1+Tau mice, we observe synaptic phagocytosis by 
microglia (Fig 2H).  
 
Cooperative effects of A and tau on behaviour and transcription are ameliorated by lowering tau levels 
in APP/PS1+Tau mice  
To determine whether the phenotypes observed in APP/PS1+Tau mice could be ameliorated by lowering 
tau levels, a cohort of mice were treated with doxycycline (dox) from 10.5 to 14.5 months to suppress 
tau transgene expression. Dox treatment lowered tau expression by 65% in APP/PS1+Tau mice (Fig 3A).  
While this lowering of human tau levels was not complete and remained higher than endogenous 
mouse tau levels would be in a wild-type mouse, it completely ameliorated the hyperactivity phenotype 
in APP/PS1+Tau mice (Fig. 3B,C). Doxycycline treatment also ameliorates gene expression changes in 
APP/PS1+Tau mice (Fig. 3D,E) and reverses the mild changes in Tau mice (Fig. S3), indicating that 
  6 
lowering tau levels protects against gene expression changes. Pathway analysis reveals a striking 
amelioration of the top 15 most up and down regulated networks in APP/PS1+Tau mice treated with dox 
(Fig. 3E). 
 
To test whether the recovery of gene expression with tau suppression was due to a prevention of 
further changes with age or a recovery of existing changes at the time treatment began, we analysed a 
subset of transcripts by RT-PCR at 9-10 months of age (an age before treatment started) and validated 
the RNA-seq data with RT-PCR in 14.5 month old brain samples that had been treated with vehicle or 
dox. The subset of genes tested indicate that the amelioration of gene expression changes with dox was 
due to a prevention of further worsening and not a recovery (Fig. S3). Since many of the upregulated 
inflammatory genes are expressed in glia, we examined astrocyte and microglial burdens. In agreement 
with the RNA-seq observation that upregulated genes are driven largely by Aß without an additive effect 
of tau, an increase in gliosis was observed in both genotypes with human Aß, APP/PS1+Tau and APP/PS1 
mice. The burden of gliosis did not recover with dox treatment, however many of the inflammatory 
markers expressed by glia were reduced with tau suppression, which may contribute indirectly to the 
recovery of the levels of synaptic genes involved in glutamatergic signalling (Fig 3E). In particular, the 
increases in transcripts involved in the complement system are normalized by dox treatment (Fig. S3), 
which is of interest due to the recent links between complement and pruning of synapses in mice 
expressing frontotemporal dementia associated mutant tau (Dejanovic et al., 2018, Litvinchuk et al., 
2018). 
 
To examine whether the increased distance travelled by APP/PS1+Tau mice was due to anxiety, we 
examined the distance travelled in the inner versus outer portions of the arena. Mice of all genotypes 
spend approximately 10 times more time in the outer than inner arena indicating a typical avoidance of 
open areas (Fig. S2). At 14.5 months of age (after treatment), there was no significant effect of genotype 
or treatment on distance travelled in the inner arena (2-way ANOVA genotype F[3,69]=1.854, treatment 
F[1,76]=0.204, interaction F[2,69]=0.153, p>0.05). In the outer arena, there were significant effects of 
genotype, treatment, and an interaction between genotype and treatment on distance travelled. 
APP/PS1+Tau vehicle treated mice travelled significantly further in the outer arena than all other groups.  
This indicates a potential anxiety phenotype as well as hyperactivity, which recovers with doxycycline 
treatment. 
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Tau in synapses may mediate behavioural and transcriptional changes 
To examine the brain changes underpinning the recovery of behaviour with tau suppression, post-mortem 
studies of pathological and molecular changes were carried out in the cohort of mice that had undergone 
treatment. Amyloid plaque pathology is unchanged with tau suppression (Fig. S4). The ThioS plaque 
burden, cross sectional area of individual ThioS stained plaques, AW7 immunostained plaques (which 
label both the dense core and oligomeric halo surrounding the core), and the area of the oligomeric Aß 
halo surrounding plaques were all unchanged with dox treatment. Expression of APP measured by qPCR 
was increased in APP/PS1+Tau mice compared to APP/PS1 littermates and this increase was ameliorated 
by tau transgene suppression. Soluble levels of Aß 42 peptide however, were not different in APP/PS1+Tau 
mice compared to APP/PS1 mice, and although there was a significant effect of treatment across groups, 
post-hoc tests show no difference between APP/PS1+Tau vehicle and dox treated mice in Aß 42 levels 
(Fig. S4). These data indicate that the behavioural and gene transcription recovery was not mediated by 
reducing amyloid pathology. 
Synapse density around plaques and the accumulation of synaptic Aß and tau were determined in 
entorhinal cortex using array tomography. More than 673,000 postsynaptic densities labelled with PSD95 
and 415,000 presynaptic terminals labelled with synaptophysin were analysed from cortical samples from 
4-11 mice per group (average 13,000 PSDs and 9,655 presynaptic puncta per mouse). Density of both 
synaptophysin (Fig 4) and PSD95 (Fig. S5) labelled puncta was decreased near plaques in the two 
genotypes that have plaques (APP/PS1 and APP/PS1+Tau mice, 3-way ANOVA effect of plaque distance 
synaptophysin F[1,42]=60.49, p<0.0001, PSD95 F[1,50]=8.15, p=0.006). Treatment with doxycycline to 
reduce tau levels did not prevent this plaque-associated synapse loss. The density of pre and post 
synapses near plaques was not significantly different between treatment groups or genotypes.  
Oligomeric Aß accumulated in a subset of synapses near plaques in both APP/PS1 and APP/PS1+Tau mice 
(median presynaptic terminals near plaques containing Aß 1.9% in APP/PS1 mice, 0.8% in APP/PS1+Tau 
mice; median postsynaptic terminals 1.0% in APP/PS1 mice, 2.4% in APP/PS1+Tau mice). The percentage 
of both pre and postsynaptic terminals containing Aß was higher near plaques in both APP/PS1 and 
APP/PS1+Tau mice (independent samples Mann-Whitney U test PSD95 p<0.01, synaptophysin p<0.0001 
for all groups near vs far from plaques). The percentage of synapses containing Aß near plaques was not 
different between APP/PS1 and APP/PS1+Tau mice (independent samples Mann-Whitney U test p>0.05). 
There was also no effect of lowering tau levels on accumulation of Aß in synapses near plaques 
(independent samples effect of treatment, Mann-Whitney U test p>0.05).   
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Tau was detected in median of 0.4% of presynapses (Fig.4E) and 1.2% of PSDs (Fig. S5) in vehicle treated 
APP/PS1+Tau mice and 1.1% of presynapses and 0.6% of PSDs in vehicle treated Tau mice. Tau was not 
detected in synapses in mice that did not express tau (control and APP/PS1). Unlike Aß, the percentage of 
synapses containing tau was not different near plaques in the APP/PS1+Tau group. The percentage of 
synapses containing tau were significantly different between genotypes (independent samples Mann-
Whitney U test for genotype p<0.0001). Doxycycline treatment significantly lowered synaptic tau levels 
only in the APP/PS1+Tau group (data split by genotype, effect of treatment independent samples Mann-
Whitney U test p=0.004 for PSD95, p=0.004 synaptophysin). The approximate 30-fold reduction in 
presynaptic and 8-fold reduction in postsynaptic tau levels in APP/PS1+Tau mice may contribute to the 
improved hyperactivity phenotype and ameliorated transcriptional profiles observed in mice treated with 
doxycycline. However this will need to be confirmed in future studies as treatment lowered tau levels 
globally, not just in synapses. Only very rare PSDs stained for both Aß and tau (<0.006% of pre <0.005% 
post synapses in vehicle treated APP/PS1+Tau mice). 
Tau is present in pre and post synapses of human AD cases 
To confirm the translational relevance of the contribution of synaptic tau to cognitive decline in our 
model, we examined the localization of tau and Aß at synapses in samples of superior temporal gyrus 
from human subjects. In total 99,967 postsynapses and 100,012 presynapses from 6 AD and 6 control 
subjects were examined (mean 8,331 post and 8,334 presynapses examined per case, data found in table 
S4). Cases were stained with the pan-Aß antibody AW7, a total tau antibody, a presynaptic marker, and a 
postsynaptic marker in a two-day protocol to allow localization of Aß and tau together within individual 
pre and postsynapse. As previously reported, Aß is present in a subset of synapses in AD brain (Koffie et 
al., 2012, Jackson et al., 2019). In this cohort we again observe significantly more positive synapses within 
20 m of a plaque (median 10.4% PSD and 8.0% synaptophysin puncta positive for Aß near plaques, <1% 
PSD or synaptophysin positive for Aß far from plaques, p<0.05 Independent samples Mann-Whitney U 
test for both pre and post synapses). In array tomography, the tau13 antibody recognized neurofibrillary 
pathology but not normal axonal tau, and labelled a small subset of pre and post-synapses (Fig. 5). As 
observed in the mice, tau synaptic localization was not different near versus far from plaques. Also in 
agreement with the mouse data, only very rare synapses were positive for both tau and Aß staining 
(<0.02% on average). Misfolded and phosphorylated tau were also detected in human synapses using 
array tomography staining with Alz50, MC1, and CP13 antibodies (Fig. 5G-J). 
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Discussion 
The lack of disease modifying treatments for AD remains a huge unmet clinical need. Synapse 
degeneration is the strongest pathological correlate of cognitive decline in AD and a potentially important 
driver of disease pathogenesis. Previous work by our group and others strongly implicated soluble Aß and 
tau separately in synapse dysfunction and loss in AD (Spires-Jones and Hyman, 2014, Klein, 2013, Koffie 
et al., 2012, Koffie et al., 2009, Kopeikina et al., 2012, Mucke and Selkoe, 2012, Spires-Jones et al., 2017). 
Here we tested the hypothesis that Aß and tau act together to cause neural circuit dysfunction. Evidence 
has been growing to support this idea from work showing that lowering tau levels protects against Aß 
mediated synaptic plasticity deficits, from studies indicating that dendritic tau mediates Aß 
synaptotoxicity, and from a study that found synaptic tau phosphorylation in APP/PS1 mice (Roberson et 
al., 2011, Shipton et al., 2011, Roberson et al., 2007, Ittner et al., 2010, Zempel et al., 2010, Wu et al., 
2018).  Recent work in a mouse model expressing both APP/PS1 and P301L mutant tau which is associated 
with frontotemporal dementia showed that reducing levels of mutant tau prevents neuronal loss (DeVos 
et al., 2018a). In our APP/PS1+Tau model, the tau expressed is wild-type human tau without endogenous 
mouse tau making this relevant to early Alzheimer’s disease. 
In this APP/PS1+Tau model, we observe an age-related hyperactivity phenotype and downregulation of 
genes involved in synaptic function. Pathologically, we observe tau in both pre and post synapses in 
human brain and in our APP/PS1+Tau model. Tau was very rarely colocalised with Aß within individual 
synapses.   Reducing tau expression levels ameliorated the behavioural and gene expression phenotypes 
and lowered synaptic tau levels without recovering synapse density around plaques. Importantly, 
doxycycline treatment of our mice did not completely remove human tau indicating that a partial 
reduction in tau levels may be sufficient in humans to allow some functional recovery. This may be more 
achievable than complete knockdown and could also preserve physiological functions of tau. Together, 
these data support the hypothesis that Aβ and tau act together to cause synapse dysfunction. However, 
this interaction is not likely to be due to physical colocalization of small aggregates of these pathological 
proteins within the same synapses, at least within the limits of our detection.   
 
We surprisingly observed that human tau expression in the absence of mouse tau resulted in smaller 
plaques in APP/PS1+Tau mice, whereas we previously saw that adding human tau with the same 
transgenic line when endogenous mouse tau is still present resulted in slightly larger plaques (Jackson et 
al., 2016).  This implies that either mouse and human tau function differently in mouse brain, that the 
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overexpression of human tau results in different effects than endogenous levels of mouse tau, or that the 
temporal and spatial expression pattern driven by the CamKIIα promotor does not recapitulate accurately 
the physiological expression of endogenous tau. Together these data highlight the importance of 
examining multiple models including knock-in lines (Sasaguri et al., 2017) and of using human post-
mortem tissue as well as mouse models to ensure the translatability of findings.  
Potential molecular mechanisms linking Aß and tau to synapse and circuit dysfunction include calcium 
dysregulation and calcineurin activation, which are known to contribute to Aß toxicity and spine collapse 
in vitro and in vivo and have been linked to tau mediated synapse impairment (Wu et al., 2010, Hudry et 
al., 2012, Kuchibhotla et al., 2008, Mattson et al., 1992, Zempel et al., 2010, Yin et al., 2016).  Human tau 
expression further causes circuit hypoactivity, even in APP/PS1 mice which usually exhibit hyperactive 
neurons (Busche et al., 2019). These data are in line with our current study as both show cooperativity 
between A and tau in impairing neuronal activity and circuit function. 
Abnormal activation of synaptic receptors by Aß has also been shown to induce activation of kinases 
including Fyn and GSK3-ß which affect tau phosphorylation and synapse collapse (Purro et al., 2012, 
Lovestone et al., 2014, Small and Duff, 2008, Marzo et al., 2016, Sellers et al., 2018, Ittner et al., 2010, 
Roberson et al., 2011). Our RNA-seq results add to the literature implicating cellular prion protein at the 
interface between Aß and tau as increases in PrPc mRNA in APP/PS1+Tau mice was the largest change 
observed with RNA-seq and these levels recover with tau suppression. PrPc has been shown to interact 
with oligomeric Aß where it is thought to act via metabotropic glutamate receptor 5 complexes to impair 
synaptic function (Haas and Strittmatter, 2016, Jarosz-Griffiths et al., 2016, Barry et al., 2011, Hu et al., 
2018, Hu et al., 2014). This pathway could involve tau since binding of Aß to PrPc can activate Fyn and 
cause tau phosphorylation (Um et al., 2013, Um et al., 2012). While many of the proposed mechanisms of 
synapse degeneration focus on postsynaptic processes, our data clearly show accumulation of both Aß 
and tau in pre as well as postsynaptic terminals. Tau has recently been shown to bind to presynaptic 
vesicles in human AD and Drosophila models, where it impairs neurotransmitter release (Zhou et al., 2017, 
McInnes et al., 2018). Similarly, it is also becoming clear that Aß exerts effects on presynaptic function 
(Ovsepian et al., 2018).  
Our RNA-seq results strongly implicate non-neuronal cells as key participants in the interplay between Aß 
and tau, which is of interest  in the field (Henstridge et al., 2019). TREM2, clusterin, and CD33, genes 
involved in the innate immune system that have been implicated in AD risk by GWAS studies, were 
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elevated in APP/PS1+Tau mice compared to controls.  Several members of the complement cascade family 
were also changed in APP/PS1+Tau mice, which is important due to the recent discovery of complement 
mediated microglial engulfment of synapses in plaque bearing AD model mice (Hong et al., 2016, Shi et 
al., 2017). Previous data on transcriptional changes in amyloid models compared to tau models 
demonstrated that changes in immune gene expression correlated positively with amyloid pathology and 
decreases in synaptic gene expression correlated with neurofibrillary tangle pathology (Matarin et al., 
2015). Our data indicate that beyond contributing to disease risk, presumably through amyloid, the innate 
immune system is also likely involved in the cascade from amyloid to tau in AD pathogenesis. The gene 
changes observed in our model indicate that Aß and tau act cooperatively to cause downregulation of 
genes and largely independently in gene upregulation. Downregulated genes were predominantly 
involved in excitatory synaptic function, which is supported by recent data implicating tau in toxicity to 
excitatory over inhibitory neurons (Fu et al., 2017).   
We propose that the inflammatory milieu initiated by amyloid primes the system making synapses 
vulnerable to tau-associated molecular changes such as loss of synaptic proteins. In the absence of 
amyloid pathology, our tau expressing mice do not develop loss of synaptic protein expression or 
behavioural abnormalities despite accumulation of tau in synapses, whereas APP/PS1+Tau mice have 
synaptic tau in the context of an inflammatory reaction to Aß which could drive behavioural phenotypes 
and loss of synaptic proteins. Interestingly, recent work in mice expressing dementia-associated mutant 
tau indicates that the complement system is involved in neurodegeneration, however reducing microglial 
numbers by inhibiting CSF1R did not ameliorate degenerative phenotypes (Bennett et al., 2018, Dejanovic 
et al., 2018, Litvinchuk et al., 2018). Thus while mutant tau may be sufficient to induce inflammatory 
phenotypes that contribute to degeneration in mice, in the context of Alzheimer’s disease, it may be that 
amyloid induces inflammatory changes which exacerbate degeneration when tau is present. Our data also 
suggest that synaptic proteins may be cleared at least in part by microglial phagocytosis. 
Synapses are highly plastic structures, which have the potential for recovery with interventions. Indeed, 
most successful drugs used in nervous system disorders act at the synapse; therefore synaptic changes 
are an obvious target for disease-modifying agents in neurodegenerative disorders. Recent work has 
focused on removing Aß from synaptic receptors as a therapeutic avenue. For example, a compound that 
displaces Aß from sigma-2 receptors is now in clinical trials (Izzo et al., 2014, Grundman et al., 2019), 
(clinicaltrials.gov/ct2/show/NCT03507790). Our data indicate that lowering pathological tau or blocking 
the inflammatory changes that may link amyloid and tau toxicity may also be effective therapeutic 
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strategies. 
Acknowledgements 
We thank our human brain tissue donors and their families for their valuable contributions to this 
work. Many thanks also to Prof George Carlson and Ms Rose Pitstick for their input on mouse breeding 
and providing mouse lines and to Dominic Walsh and Peter Davies for providing antibodies.  This work 
was funded by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by 
the UK Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research UK, the European 
Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme 
(Grant agreement No. 681181), Alzheimer’s Research UK and the Scottish Government Chief Scientist 
Office (ARUK SPG2013-1), a Wellcome Trust-University of Edinburgh Institutional Strategic Support 
Fund, MND Scotland, and Alzheimer’s Society.  SD contributed to this work funded by an Alzheimer’s 
Society summer studentship. MF contributed to this work funded by a summer studentship from 
Medical Research Scotland. TSJ gratefully acknowledges affiliations with the Centre for Dementia 
Prevention, the Euan MacDonald Centre, and Edinburgh Neuroscience. Two of the control participants 
in the human study were from the Lothian Birth Cohort 1936, thus we wish to thank the cohort and 
research team supported by Age UK (Disconnected Mind project) in The University of Edinburgh Centre 
for Cognitive Ageing and Cognitive Epidemiology, funded by the Biotechnology and Biological Sciences 
Research Council (BBSRC) and Medical Research Council (MRC) ((MR/K026992/1). We acknowledge that 
the graphical abstract was created with Biorender software. 
 
Author Contributions 
Conceptualization, G.H. and T.L.S-J.; Methodology, E.K.P., J.T., G.A.C., and T.L.S.-J., Software, T.L.S.-J., 
M.C.C. and E.A.; Formal Analysis, O.D., M.H., I.O. G.E.H. and T.L.S.-J.; Investigation, E.K.P., J.M., K.A., J.T., 
A.G.H., P.J., S.D., S.S.S., A.S., M.F., W.C., L.M., R.J.J., M.T., M.D’O.,  J.R., R.P., C.-A.M., M.C.C., A.A., C.S., 
and C.M.H; Writing – Original Draft, E.K.P, and T.L.S.-J.; Writing – Reviewing & Editing, C.M.H, G.H., and 
T.L.S.-J.; Supervision, I.O., O.H., G.H., and T.L.S.-J.; Funding Acquisition G.H., and T.L.S.-J. 
Declaration of interests 
T.L.S-J. receives funding from 3 industry collaborators and is on the Scientific Advisory Board of Cognition 
Therapeutics. None of these companies had any influence over the current work. 
FIGURE LEGENDS 
  13 
Fig. 1. Progressive plaque pathology without tau pathology in APP/PS1+Tau mice. The APP/PS1+Tau 
mouse model was generated by breeding two feeder lines to produce four experimental genotypes of F1 
littermates on a consistent outbred strain background (A). Behavior, pathology, and recovery with tau 
transgene suppression were characterized over time (B). Staining with Thioflavin S (C) shows progressive 
plaque accumulation in APP/PS1+Tau and APP/PS1 mice. APP/PS1+Tau mice have significantly lower 
cortical plaque burden than APP/PS1 mice (D, 2 way ANOVA effect of genotype F[2,26]=8.454, p=0.007). 
Tau is present in 14.5 month old APP/PS1+Tau mice as shown with a total tau stain, but tau pathology 
does not accumulate in cell bodies or in dystrophic neurites around plaques as shown by staining with 
phospho-tau (PHF1 and AT8), or misfolded tau (Alz50) antibodies, which all label tangle pathology in 
rTg4510 positive control sections (E). None of the genotypes experienced age related cortical atrophy (F, 
2-way ANOVA effect of age, p>0.05). Data shown are means +/- standard error. Dots on bar graphs 
represent means of individual animals (n per group, biological replicates, shown in each bar). Scale bars 
represent 1mm (c, insets 100x100 µm), 30 µm (e). See also Figure S1 and table S1. 
 
Fig. 2: Hyperactivity and transcriptional changes in APP/PS1+Tau mice. The open field test was used as 
a measure of spontaneous activity. Representative traces from a mouse from each genotype at 10.5 
months of age (A), demonstrate the excess activity of the APP/PS1+Tau mice compared to the other three 
genotypes (B, Two-way ANOVA effect of genotype (F[3,202]=314.76, p=0<0.0001, * Tukey’s post hoc tests 
p<=0.01 all comparisons of APP/PS1+Tau vs other 3 genotypes at 10.5 and 14.5 months, n of mice as 
biological replicates per group are noted on the graph). Dotted line in B indicates a different cohort of 
mice was used at 3-6-9 and 10.5-14.5 months. RNA-seq of APP/PS1 brain compared to controls reveals 
significant changes in gene expression (C, FPKM, Fragments Per Kilobase of transcript per Million mapped 
reads, biological replicates were mice, n=5 per group). Wild-type human tau induced changes to a lesser 
extent (D).  APP/PS1+Tau mice (E) had more significant changes than when either APP/PS1 or Tau were 
expressed on their own. Transcripts changed more than 2 fold with an adjusted p value of p<0.05 are 
shown in red in panels C-E.  A few transcripts of interest based on previous work are labelled with gene 
names.  Examining only the genes significantly changed in APP/PS1+Tau mice compared to control mice 
and comparing the log(2) fold change (L2FC) of these on the x-axis to the maximum L2FC of either APP/PS1 
or Tau compared to controls on the y axis (F) shows that upregulated genes are for the most part not 
differentially regulated in APP/PS1+Tau mice compared to those expressing APP/PS1 or tau alone (black 
line linear regression slope 0.90, 95% CI 0.89 to 0.92, dotted red line is x=y showing expected values if 
there were no differences).  Downregulated genes in APP/PS1+Tau mice (F) are differentially regulated in 
APP/PS1+Tau mice compared to those expressing APP/PS1 or tau alone (black line linear regression slope 
0.57, 95% CI 0.51 to 0.63). Green crosses in F show transcripts of interest which are changed more in 
APP/PS1+Tau mice than in APP/PS1 or Tau mice including downregulated genes involved in synaptic 
function and upregulated genes involved in inflammation.  Each cross in C-F represents the average value 
of 5 mice per genotype of a single transcript detected at >1 FKPM.  Pathway analysis of all RNAseq data 
(G) reveals that many of the upregulated pathways in APP/PS1+Tau mice are also upregulated in APP/PS1 
mice and most downregulated pathways are also downregulated in Tau mice (orange indicates increases, 
blue decreases compared to control levels, analysis from Ingenuity Pathway Analysis software). However, 
there are pathways changed more in the APP/PS1+Tau line compared to the parent lines including 
increases in the complement system and decreases in glutamatergic signalling. Confocal imaging of Iba1 
and synaptophysin staining shows that microglia engulf synaptic proteins around plaques (H, arrows show 
localization of synaptophysin inside microglia). Scale bar shows 5 microns. See also Figure S2 and tables 
S1-S3. 
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Fig. 3: Lowering tau levels ameliorates hyperactivity phenotype and transcriptional changes. Transgene 
suppression (dox) reduced human tau mRNA levels by approximately 65% as measured by qPCR (A, * 2-
way ANOVA effect of treatment F[1,31]=42.22, p<0.0001).  Representative traces of open field activity 
from a APP/PS1+Tau mouse treated with vehicle and one treated with doxycycline and the trace from the 
same mice after treatment (B) shows a clear amelioration of hyperactivity phenotype in one mouse which 
is confirmed by quantification of distance travelled (C, repeated measures ANOVA effect of genotype 
F(3,69)=34.12, p<0.0001, effect of treatment F[1,69]=6.75, p=0.01, interaction F[3,69]=6.13, p=0.001); 
*Tukey’s multiple comparisons tests dox treated APP/PS1+Tau mice are significantly different from 
vehicle treated APP/PS1+Tau mice at 14.5 months of age (p<0.0001)). RNA-seq data show that dox 
treatment to reduce tau levels reverses transcriptional changes in APP/PS1+Tau mice (D, linear regression 
slope = -0.34, 95% CI -0.36 to -0.33). Each point represents a single transcript (average of n=5 mice per 
group). Pathway analysis reveals that the top 15 up and downregulated canonical pathways in 
APP/PS1+Tau mice compared to controls recover to normal levels or past normal levels with dox 
treatment (E, orange indicates increases, blue decreases compared to control levels, analysis from 
Ingenuity Pathway Analysis software). Biological replicates/experimental unit for each experiment is an 
individual mouse, n per group shown on the panels A and C.  See also Figures S3 and S4 and tables S1-S3. 
 
Fig. 4:  Tau suppression reduces presynaptic accumulation of tau in entorhinal cortex. To investigate 
synapse loss and synaptic proteins, array tomography ribbons from 14.5 month old mice were stained for 
presynaptic terminals (synaptophysin, green) human tau (red), and amyloid beta (AW7, cyan). Maximum 
intensity projections of 10 serial 70 nm sections of a mouse in each group are shown in A. Three-
dimensional reconstructions of 5 consecutive serial sections from processed image stacks of a 
APP/PS1+Tau mouse (B) demonstrate presynaptic terminals positive for tau (arrows) or Aß (arrowheads). 
Quantification reveals significant presynapse loss near plaques in APP/PS1 and APP/PS1+Tau mice which 
is not rescued by lowering tau levels with doxycycline (dox) treatment (C). The percentage of presynapses 
positive for Aß is not different between MAPTnullxAPP/PS1 mice and APP/PS1+Tau mice, nor is it affected 
by dox treatment (D).   The percentage of presynapses containing tau is significantly lowered by dox 
treatment in APP/PS1+Tau mice (e, * Mann-Whitney U test p=0.004). Data represent mean + SEM (C) and 
median + interquartile range (D,E). Scale bars represent 10 m in A, 1 m in B. Each dot on the graphs 
represents the mean (C) or median (D,E) of a single mouse (biological replicate/experimental unit = 
mouse, n’s shown on each panel). See also Figure S4 and S5 and table S1. 
 
Fig. 5: Tau is found in pre and postsynapses in human AD brain.  Array tomography was used in human 
AD and control postmortem brain tissue to stain Aß (white), Tau13 (yellow), PSD95 (magenta), and 
synaptophysin (cyan) (A-D).  Tau13 stains neuropil threads (arrows, A).  Examining individual synapses 
revealed that A was present in 8.0% of presynaptic terminals (B, arrowheads) and 10.4% of 
postsynaptic densities (B arrows) near plaques in AD cases (B,E).   Tau13 staining was observed in 0.23% 
of presynaptic terminals (arrowheads C, quantified in F), and 0.32% of postsynaptic terminals (arrows,D 
quantified in F). Misfolded tau labeled with Alz50 (G-I, yellow) was also observed in neuropil threads 
(arrows G) and in presynapses (arrowheads, H) and post synapses (arrows, I). Tau phosphorylated at 
serine 202 (labeled with CP13) and misfolded (residues 5-15 near 312-322, labelled with MC1) was also 
observed in PSDs (J). Images in A, G and large panels in J are maximum intensity projections of 10 serial 
sections.  Scale bar represents 10 µm in A, G, J. B-D, H-I, and insets in J show three-dimensional 
reconstructions of a 2x2 micron region of interest in 5 consecutive serial 70nm sections. Data shown are 
median and interquartile ranges. Each dot represents the median of a single human subject (subject is 
the biological replicate/experimental unit n=6 per group). See also table S4. 
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Table 1: Human subject characteristics  
case diagnosis age  sex 
1442 AD 80 f 
1446 AD 84 m 
1547 AD 77 m 
1564 AD 90 m 
AD5 AD 75 f 
BBN24526 AD 79 m 
HC control 66 m 
HC2 control 69 m 
HC3 control 75 m 
HC6 control 95 m 
BBN28406 control 79 m 
BBN19686 control 77 f 
 
 
Table 2: Antibodies used in array tomography and histology studies. Host species were mouse (Ms), 
Rabbit (Rb), goat (Gt), and guinea pig (Gp). 
Primary antibody Species Source (cat no) Dilution  Secondary antibody 
Mouse pathology study for amyloid burden and cortical and hippocampal volumes 
AW7 Rb Dominic Walsh 1:5000 Donkey anti-rabbit 
Alexa594, Invitrogen 
Mouse tau pathology study (independent stains)  
PHF1 Ms P Davies 1:1000 Donkey anti-mouse 
Alexa594, Invitrogen 
Alz50 Ms IgM P Davies 1:1000 Donkey anti-mouse IgM 
Alexa594, Invitrogen 
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AT8 Ms Thermo Fisher 
MN1020 
1:1000 Donkey anti-mouse 
Alexa594, Invitrogen 
Mouse study of gliosis burden 
Iba1 
 
 
 
Gt Abcam ab5076 1:500 Donkey anti-goat  
Alexa647, abcam 
GFAP Rb DAKO Z0334 
 
1:2000 Donkey anti-rabbit  
Alexa594, abcam 
Mouse study of synaptic proteins inside microglia 
Synaptophysin Ms Abcam Ab8049 1:500 Donkey anti-mouse 
Alexa594, Invitrogen 
Iba1 
 
 
 
Gt Abcam ab5076 1:500 Donkey anti-goat  
Alexa647, abcam  
 
Mouse array tomography study of postsynaptic density and protein colocalisation 
PSD95 Rb Cell signaling 
3450P 
1:50 Donkey anti-rabbit 
Alexa594, Invitrogen 
Tau Gt R&D Systems 1:50 Donkey anti-goat Alexa647, 
Invitrogen 
1C22 Ms D Walsh 1:500 Donkey anti-mouse 
Alexa488, Invitrogen 
Mouse array tomography study of presynaptic density and protein colocalisation 
synaptophysin Ms Abcam   
AB8049 
1:50 Donkey anti-mouse 
Alexa594, Invitrogen 
Tau Gt R&D Systems 
AF3494 
1:50 Donkey anti-goat Alexa647, 
Invitrogen 
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AW7 Rb D Walsh 1:500 Donkey anti-Rabbit 
Alexa488, Invitrogen 
Human array tomography study of Tau13 synapse localization day 1 
synaptophysin Ms Abcam  
AB8049 
1:50 Donkey anti-mouse 
Alexa488, Invitrogen 
PSD95  Rb Cell signaling  
3450P 
1:50 Donkey anti-rabbit 
Alexa594, Invitrogen 
Human array tomography study of total tau synapse localization day 2 
Tau13 Ms Covance  
MMS-520R 
 Donkey anti-mouse 
Alexa488, Invitrogen 
AW7 Rb D Walsh 1:500 Donkey anti-Rabbit 
Alexa594, Invitrogen 
 
STAR METHODS 
LEAD CONTACT AND MATERIALS AVAILABILTY 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 
the Lead Contact Prof Tara Spires-Jones (tara.spires-jones@ed.ac.uk).  The new mouse line generated for 
this project was made using breeding of existing lines and in some cases material transfer agreements will 
be needed from the line originators before we can share lines. 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Animals All animal experiments conformed to national and institutional guidelines including the Animals 
[Scientific Procedures Act] 1986 (UK), and the Council Directive 2010/63EU of the European Parliament 
and the Council of 22 September 2010 on the protection of animals used for scientific purposes, and had 
full Home Office ethical approval.  Mice were bred in house and group housed in a 12h/12h light/dark 
cycle with ad libitum access to food and water.  Both sexes of mice were used in all experiments (see table 
S1 for details of all mice used including sex, age, and weight information).  Littermates were randomly 
assigned to experimental groups in experiments to reduce tau transgene expression and experimenters 
were blinded to genotype and treatment. 
Human subjects Brain tissue samples were taken from superior temporal gyrus of 6 AD and 6 control 
subjects in the Edinburgh Sudden Death Brain Bank or the Massachusetts General Hospital Alzheimer’s 
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Disease Research Centre Brain Bank.  Characteristics of human subjects can be found in table 1 and 
synapse data in table S4. Average age was 81 for AD cases (range 75-90) and 77 for control cases (range 
69-95).  All AD cases were neuropathologically confirmed and were Braak stage V or VI.  Control cases had 
no neurological phenotype.  All human experiments were reviewed and approved by the Sudden Death 
Brain Bank ethics committee and the ACCORD medical research ethics committee (Academic and Clinical 
Central Office for Research and Development at the University of Edinburgh and National Health Service 
Lothian, ethical approval number 15-HV-016). 
METHOD DETAILS 
Generation of mouse line: 
For the MAPTnull APP/PS1 rTg21221 (APP/PS1+Tau) model line, 4 genotypes were used to compare mice 
with (1) no transgene expression on a MAPTnull background (controls), (2) mice expressing human familial 
AD mutant APP and PS1 to generate Aß pathology (APP/PS1), (3) mice expressing 0N4R wild-type human 
tau (Tau), and (4) mice expressing both human tau and the APP/PS1 transgene (APP/PS1+Tau, Fig. 1). All 
mice were homozygous for deletion of mouse tau and heterozygous for the human wild-type tau 
transgene which is only expressed when the tetracycline transactivator transgene is also present.  All 
experimental mice were F1 crosses from two feeder lines to maintain a controlled outbred background 
strain with consistent proportions of B6, B6C3, and FVB backgrounds.  Parent strains used to generate the 
APP/PS1+Tau feeder lines were: (1) B6C3 APP/PS1 mice expressing human APP with the Swedish mutation 
and human presenilin 1 with an exon 9 deletion under the control of the Thy1 promoter (B6C3-
Tg(APPsw,PSEN1dE9)85DboMmjax, Jax 34829) (Jankowsky et al., 2004);   (2) MAPTnull mice which have 
the first exon of the Mapt gene replaced with EGFP (Tucker et al., 2001); (3) mice expressing the 
tetracycline transactivator under the control of the calcium calmodulin kinase 2 alpha promoter CK-tTA 
on the C57BL/6 backgrounds strain (B6.Cg-(Camk2a-tTA)1/MmayDboJ ,(Yasuda and Mayford, 2006));  (4) 
Tg21221 mice expressing human wild type tau under a dox-off tetracycline transactivator promotor (FVB-
Tg(tetO-0N4R-MAPTwt)21221, (Hoover et al., 2010)). One feeder line was generated by crossing 
FVB.MAPTnull mice with the FVB.Tg21221 mice to generate FVB Tg21221 MAPTnull mice homozygous for 
both the Tg21221 transgene and the MAPT knockout. The other feeder line was generated by crossing 
B6C3 APP/PS1 mice with B6 MAPTnull mice to generate mice heterozygous for the APP/PS1 transgene 
and homozygous for the MAPT knockout.  These two feeder lines were bred to generate F1 experimental 
animals. Human tau is only expressed when the tetracycline transactivator is also expressed and can be 
suppressed by feeding the mice doxycycline (Fig 1a). This consistent outbred background breeding scheme 
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keeps variability low while avoiding potential pitfalls of inbred strains such as sensory deficits during 
ageing, liver deficits, deletions such as loss of alpha-synuclein in some C57 strains, and other unknown 
recessive defects that may occur in inbred lines (Specht and Schoepfer, 2001, Cudalbu et al., 2013, Wong 
and Brown, 2006). Out of the 395 mice born during the generation and phenotyping of the APP/PS1+Tau 
line, as expected 100% were homozygous for endogenous tau knockout, 100% were heterozygous for the 
rTg21221 tau responder transgene, 53% were heterozygous for the APP/PS1 transgene (50% expected), 
48% were heterozygous for the CK-tTA activator transgene (50% expected), and 23% had both the 
APP/PS1 and CK-tTA transgenes (25% expected).  48% of the mice were female. Thus, the transgenes were 
all inherited in the expected Mendelian ratios, indicating that no combination of genotypes was lethal (Chi 
squared value = 6.41, p= 0.093, df = 3 confirming Mendelian ratios).  This is an important advantage of 
our consistent outbred breeding scheme as the same APP/PS1 transgene is lethal to about half of the mice 
on a congenic B6 background (Bennett et al., 2017). Genotyping of mice was carried out on ear notch 
samples using PCR primer sequences found in table S5. 
 
One cohort of mice was aged and used for behavioural testing at 3, 6, and 9-10 months of age and 
sacrificed at 9-10 months of age for pathological characterization (see tables S1, S2, and S3 for all mouse 
data). Another cohort of mice was aged to 10-10.5 months of age, tested for baseline behaviour, then half 
of the mice were treated with 200ppm doxycycline in the chow for 4 months to reduce tau transgene 
expression and the others treated with control chow (vehicle). These mice underwent behavioural testing 
again at at 14-14.5 months of age then were sacrificed for pathological and molecular studies.  Another 
cohort of littermates was aged to 6 months and sacrificed to look at onset of pathology. 
As a negative control to be sure that any effects of tau expression were not an artefact of the CKtTA 
activator transgene, which is expressed in all mice that express tau by necessity, we examined B6.CKtTA 
mice on a mouse tau null background at 9 months of age for behavioural and pathological changes.  As a 
positive control for tau staining rTg4510 brain sections from 3 mice were used for tau 
immunohistochemistry (Santacruz et al., 2005, Spires et al., 2006).  
 
Behavioural testing 
Group sizes for behavioural studies in the APP/PS1+Tau line can be found in figure legends and table S1.  
We used distance travelled in an open field to determine whether mice had a hyperactivity phenotype as 
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has been used by multiple groups previously as a proxy for hyperactivity in AD model mice (see for 
example Blackmore et al., 2017, Yetman et al., 2016). Animals were tested for open field behaviour in a 
square box (40 x 40 x 60 cm) composed of dark opaque walls with approximately 2.5cm of corn cob 
bedding on the floor of the arena. Animals were recorded using an overhead camera and the video signal 
fed into Blackmagic Media Express computer software which captured the animals’ movements. Each day 
animals were brought into the testing room in their home cage upon the end of the 12 hr dark cycle and 
allowed to settle for 1 hour. For habituation, animals were exposed to the open field for 3 consecutive 
days. On day 1, animals were introduced to the centre of the arena along with cage mates for 20 minutes. 
For days 2-4, individual animals were placed facing a corner of the arena, which was assigned using a 
random generator. For each experimental group, the order in which animals were placed in the arena was 
randomly assigned using a random sequence generator.  On day 4, behaviour in the open field was 
recorded for 10 minutes using an overhead camera and movements captured with Blackmagic Media 
Express software. idTracker software and MATLAB were used to analyse mouse behaviour. The total 
distance travelled, distance travelled in the outer segment (40 x 40 – inner segment), distance travelled 
in the inner segment (20 x 20), percentage of time spent in the outer segment and percentage of time 
spent in the inner segment, were calculated and analysed in SPSS and Prism7.  
 
In order to ensure that the hyperactivity observed at 14.5 months of age is not a consequence of baseline 
performance prior to treatment, 10.5 month old mice were assessed for baseline performance in the open 
field according to the treatment group to which they would be assigned. A significant effect of genotype 
was observed (p<0.0001), however there was no difference in open field behaviour in the cohorts 
destined for doxycycline or vehicle treatment within the same genotype (2-way ANOVA effect of 
treatment F(1,164)=0, p>0.99999). This suggests the increase in total distance travelled in 14.5 month old 
vehicle-treated APP/PS1+Tau mice and reversal with doxycycline is not due to baseline increased activity 
in this group at 10.5 months of age.   
 
 
Measuring pathology 
Mice were sacrificed by terminal anaesthesia and perfused with PBS.  Brains were dissected and one 
hemisphere fixed for 48 hours in 4% paraformaldehyde.  Samples of entorhinal cortex from the other 
hemisphere were saved for array tomography as detailed below and the rest of the hemisphere was 
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frozen for biochemical analyses.  The fixed hemisphere was cryoprotected in 15% glycerol and sectioned 
into 50 micron coronal sections through the entire hemisphere with a sliding microtome (Leica SM2010R 
sliding microtome). To quantify amyloid pathology, every 20th section was stained with a pan-Aß antibody 
and counterstained with 0.05% Thioflavine S in 50% ethanol to label plaque fibrils and any neurofibrillary 
tangles (antibody details are found in table 2).  Tile scan images of each entire section were obtained with 
a 10x objective on a Zeiss Axioimager microscope.  Images were analysed using ImageJ.  The cortex and 
hippocampus on each section were outlined, regions of interest defined, and the area calculated.  Cortical 
and hippocampal volumes were estimated by multiplying the area on each section by 1000 (distance 
between sections), summing these values for all sections, and multiplying by 2 to estimate total volume 
as we only measured one hemisphere. Each channel of amyloid staining was manually thresholded in 
ImageJ by an experimenter blinded to genotype. The ImageJ analyze particles function was used to 
calculate the percent area of cortex and hippocampus occupied by staining and the number and average 
size of individual plaques.  To calculate the burden of oligomeric halos surrounding plaques, the 
thresholded Thioflavin S image was subtracted from the thresholded pan-Aß image and plaque burden, 
number, and size were analysed as above. 
Series of every 10th section were also stained with pathological tau antibodies to look for neurofibrillary 
tangles and neuropil threads as detailed in table 2.  Stained sections were examined using a Zeiss 
AxioImager Z2 microscope and images acquired with a CoolSnap digital camera.  For tau stains, rTg4510 
mouse brain sections containing neurofibrillary pathology were used as positive controls. 
To measure gliosis burden, free floating coronal sections were stained for microglia (Iba1), astrocytes 
(GFAP), and fibrillary plaques (Thioflavine S), with citrate buffer pre-treatment (95oC for 20 minutes, see 
table 2 for antibody details). Three coronal sections were stained per mouse at approximately 0.75mm, -
2.0mm, and -3.75mm from Bregma. Tile scans were obtained at 10x magnification using a ZEISS Imager.Z2 
microscope and images were thresholded on ImageJ for cortical burden quantification.  For all 
immunostains, no primary conditions were used as negative controls. 
To examine synaptic proteins within microglia, 2 coronal sections per mouse (Bregma -1.0 and -3.0, n=5 
mice per group) were stained for microglia (Iba1), synaptophysin (SY38), DAPI, and fibrillar plaques 
(Thioflavine S 0.05% in 50% ethanol). Citrate buffer pre-treatment was used for antigen retrieval (95oC for 
20 minutes, see table 2 for antibody details). Confocal image stacks were acquired on a Leica TCS SP8 
confocal with z-step of 1 micron.  Z-stack reconstructions were performed in ImageJ and Imaris to confirm 
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synaptic proteins within Iba1 positive cells. 
RNA analyses 
Total RNA was extracted from the frontal cortex using the Lipid Tissue Mini Kit (Qiagen). RNA quantity and 
quality was assessed using a Bioanalyzer 2100 (Agilent Technologies). All samples had RIN values > 7. To 
generate RNA-seq data, barcoded RNA-seq libraries were prepared by Edinburgh Genomics using the 
Illumina TruSeq stranded mRNA-seq kit, according to the manufacturer’s protocol (Illumina). The libraries 
were pooled and sequenced using an Illumina Novaseq 6000. RNA-sequencing was performed to a depth 
of ~60 million 50bp paired-end reads per sample.  Reads were mapped to the mouse primary genome 
assembly (GRCm38) contained in Ensembl release 92 (Zerbino et al., 2018). Read alignment was 
performed with STAR (Dobin et al., 2013), version 2.5.3a, and tables of per-gene read counts were 
generated from the mapped reads with featureCounts (Liao et al., 2014), version 1.5.2. Differential 
expression analysis was then performed using DESeq2 (R package version 1.18.1) (Love et al., 2014). Gene 
Ontology enrichment analysis was performed with topGO [5] (R package version 2.30.1), and pathway 
analyses were performed with Ingenuity Pathway Analysis software (Krämer et al., 2013). An adjusted p 
value cut-off of <0.05 was set to identify molecules whose expression was differentially regulated. 
 
For qRT-PCR, cDNA was synthesised using the SuperScript VILO cDNA synthesis kit (ThermoFisher) and the 
following PCR settings used: 10 minutes at 25°C, 60 minutes at 42°C and 5 minutes at 85°C. qPCRs were 
run on a Stratagene Mx3000P QPCR System (Agilent Technologies) using SYBR Green MasterRox 
(Roche) with 6 ng of cDNA per well of a 96-well plate, using the following programme: 10 min at 95 °C, 
40 cycles of 30 s at 95 °C, 40 s at 60 °C and 30 s at 72 °C, with a subsequent cycle of 1 min at 95 °C and 
30 s at 55 °C ramping up to 95 °C over 30 s (to measure the dissociation curve). Primers used are found 
in table S5. 
 
Array Tomography  
Fresh brain tissue samples were collected from 14.5 month old mice and human subjects as outlined 
previously (Koffie et al., 2009, Kay et al., 2013). Small tissue blocks containing cortex were fixed in 4% 
paraformaldehyde and 2.5% sucrose in 20 mM phosphate buffered saline pH 7.4 (PBS) for 3 hours. 
Samples were then dehydrated through ascending cold graded ethanol and embedded into LR White resin 
(EMS) which was allowed to polymerise overnight at 53 °C. Resin embedded tissue blocks were cut into 
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array ribbons of 70 nm thick sections using an ultracut microtome (Leica) equipped with a Jumbo Histo 
Diamond Knife (Diatome, Hatfield, PA) and collected onto gelatin coated coverslips.  
 
For pathological protein colocalisation with postsynapses, array ribbons were immunostained with 
primary antibodies against post synapses (PSD95), oligomeric A (1C22) and total tau (pan-tau). For 
pathological protein colocalisation with pre-synapses, array ribbons were immunostained with primary 
antibodies against synaptic vesicle protein synaptophysin, A (AW7) and total tau (pan-tau) (Table 2). 
Sections were counterstained with 0.01 mg/mL 4’-6-diamidino-2-phenylindole (DAPI). In each 
experiment, a short extra ribbon was used as a no primary negative control. Images were obtained on 
serial sections using a Zeiss axio Imager Z2 epifluorescent microscope with a 10x objective for tile scans 
and 63x 1.4NA Plan Apochromat objective for high resolution images. Images were acquired with a 
CoolSnap digital camera and AxioImager software with array tomography macros (Carl Zeiss, Ltd, 
Cambridge UK).  
 
Human brain array tomography ribbons were stained with combinations of synaptic antibodies, tau 
antibodies and AW7 to label amyloid beta as described in the Figs and table 2.  For two-day stains, 
antibodies applied for the first imaging day were stripped by incubation in aqueous 0.02% SDS and 0.8% 
sodium hydroxide solution for 20 minutes.  Stripped ribbons were rinsed in water and re-probed with 
another set of primary then secondary antibodies.  
Images from each set of serial sections were converted into image stacks and aligned using the Image J 
plug-in, MultiStackReg (courtesy of Brad Busse and P. Thevenaz, Stanford University) (Thevenaz et al., 
1998). Regions of interest within the cortical neuropil were chosen (10 μm2) and their proximity to plaque 
edges recorded (<20 μm from a plaque edge considered “near” plaques and >20 μm from a plaque edge 
considered “far” from plaques).  Image stacks were then binarised using thresholding algorithms in 
ImageJ. For synaptic staining, images stacks were binarised using an ImageJ script that combines different 
thresholding algorithms in order to select both high and low intensity synapses in an automated and 
unbiased manner. To calculate the synaptic density, thresholded images were processed and analysed in 
MATLAB to remove background noise (objects present in only a single section were removed). To examine 
pathological protein presence at the synapse, thresholded images were processed and analysed in 
MATLAB to remove background noise and to calculate the colocalisation of total tau and oligomeric A 
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with post synapses individually and in combination (a minimum of 50% of the synapse volume had to 
overlap with tau and/or 1C22 to qualify as positive for that stain).   
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
All experiments were carried out by a person blind to genotype and treatment of the mice and blind to 
diagnosis for human studies. For each experimental variable, a percentage, mean or median was 
calculated for each subject (experimental unit was the mouse or human case).  Groups of mice or people 
were compared with parametric or non-parametric tests as appropriate based on the normality of the 
datasets as assessed by Shapiro-Wilks tests.  Statistical tests were carried out in SPSS and Prism7. The 
number of subjects and statistical tests used for each experiment are indicated in the results, Fig legends, 
and data analysed is found in tables S1 and S2 (mouse) and S4 (human). 
 
DATA AND SOFTWARE AVAILABILITY 
 
Spreadsheets of all data used in this study are included as tables S1-S4.  The RNA-seq data generated 
during this study are available at the European Bioinformatics Institute depository 
(https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7856/). Custom imageJ and MATLAB macros 
used for image analysis are freely available on the University of Edinburgh Data Sharing repository 
(https://doi.org/10.7488/ds/2592). 
 
Supplemental files: 
table S1 – individual mouse pathology data. Related to figures 1-4. 
table S2 – mouse RNAseq results. Related to figures 2, 3. 
table S3 – canonical pathways in Ingenuity Pathway Analysis of mouse RNAseq data, related to figures 2, 
3. 
table S4 – individual human array tomography data. Related to figure 5. 
table S5 – oligonucleotides, related to STAR methods 
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 KEY RESOURCES TABLE  
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
AW7 antibody, recognises amyloid beta, polyclonal, raised in 
rabbit 
provided by Prof 
Dominic Walsh 
N/A 
PHF1 antibody, recognises human tau phosphorylated 
at Ser396/Ser404, mouse monocolnal IgG1 
provided by Prof Peter 
Davies 
N/A 
Alz50 antibody, recognises human tau folded to bring amino 
acids 2-10 and 312-342 into proximity, mouse IgM 
provided by Prof Peter 
Davies 
N/A 
AT8 antibody, recognises human tau phosphorylated 
at Ser202, Thr205, Mouse  monoclonal IgG1 
Thermo Fisher RRID:AB_223647 
Iba1antibody, Goat polyclonal Abcam  RRID:AB_2224402 
GFAP antibody, Rabbit polyclonal DAKO RRID:AB_10013382 
PSD95 antibody, rabbit monoclonal Cell signaling 
  
RRID:AB_2292883 
Tau antibody, goat polyclonal R&D Systems RRID:AB_573209 
synaptophysin antibody, mouse monoclonal Abcam RRID:AB_2198854 
Tau antibody Tau13, recognises human tau aa15-25, mouse 
monoclonal 
Covance RRID:AB_291452 
Biological Samples 
Human Brain Tissue samples Edinburgh Sudden Death 
Brain Bank or the 
Massachusetts General 
Hospital Alzheimer’s 
Disease Research Centre 
Brain Bank 
Case IDs found in 
Table 1 
Chemicals, Peptides, and Recombinant Proteins 
LR White Medium Grade Acrylic Resin Agar Scientific Cat#R1281 
Paraformeldahyde 16% Agar Scientific Cat#R1026 
Tris buffered saline 10x Fisher BioReagents  Cat#BP2471-1 
Sucrose Sigma Life Sciences Cat#S0389-1KG 
Thioflavin S Fisher Scientific Cat#15537519 
Critical Commercial Assays 
Tau ELISA Thermo Fisher Scientific Cat#KHB0041 
Amyloid beta 1-42 ELISA Thermo Fisher Scientific Cat#KHB3441 
Deposited Data 
See associated excel spreadsheets in supplemental 
data Tables S1-S4 
  
Experimental Models: Organisms/Strains 
mouse: B6C3-Tg(APPsw,PSEN1dE9)85DboMm Jackson Labs Jax 34829 
mouse:  FVB.Mapttm1(EGFP)Klt George Carlson, 
collaborator 
N/A 
mouse: B6.Cg-(Camk2a-tTA)1/MmayDboJ George Carlson, 
collaborator 
N/A 
mouse: FVB-Tg(tetO-0N4R-MAPTwt)21221 George Carlson, 
collaborator 
N/A 
Oligonucleotides 
Key Resource Table
 See table S5   
Software and Algorithms 
Fiji (Image J) v2.0.0 Open Source NIH 
software 
 
MATLAB v 2018b Mathworks  
R package version 2.30.1 r-project free software  
Ingenuity Pathway Analysis v01-14 Qiagen  
Graphpad Prism v7.0d Graphpad  
SPSS Statistics v24 IBM  
Custom imageJ and MATLAB macros used for image analysis 
are freely available on the University of Edinburgh Data 
Sharing repository  
https://doi.org/10.7488/
ds/2592 
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 Figure S1 related to Figure 1: No age-related loss of brain, weight, body weight, or hippocampal 
volume in APP/PS1+Tau mice. There was a significant effect of genotype on brain weight (A, 
F[3,163]=40.28, p<0.0001), body weight B, F[3,153]=37.25, p<0.001), and hippocampal volume (C, 
F[3,50]=4.82, p=0.005) with both tau mice and APP/PS1+Tau mice exhibiting reductions compared to 
the other 2 genotypes. Despite reduced hippocampal volume in both APP/PS1+Tau and Tau mice, 
there was no age-related reduction in hippocampal volume (C, 2-way ANOVA effect of age 
F[3,50]=0.002, p=0.997).   The reduction in brain and body weight is driven not by tau expression but 
by the CKtTA activator transgene that is needed to drive the tau transgene.  9 month old 
MAPTnullxCKtTA mice in the absence of the Tg21221 responder transgene have reduced brain (D, 
unpaired t-test t=5.144 df=16, p<0.0001) and body weights (E, unpaired t-test t=2.803 df=16, 
p=0.012).  This loss of brain and body weight did not affect total distance travelled in the open field 
(F).  Similar to the cortical data presented in Fig 1, hippocampal plaque burden was significantly 
smaller in APP/PS1+Tau mice compared to APP/PS1 mice (G, 2-way ANOVA effect of genotype 
F[1,26]=11.21, p=0.002, effect of age F[2,26]=44.19, p<0.0001). 
 
 
 
Supplemental Text and Figures
 Figure S2 related to Figure 2: Hyperactivity is not different between male and female mice and open 
field data indicate anxiety in APP/PS1+Tau mice. The hyperactivity phenotype observed in 
APP/PS1+Tau mice is not different between male and female mice (A, one-Way ANOVA effect of sex 
p>0.05 at all age groups).  To determine whether APP/PS1+Tau mice have an anxiety phenotype, open 
field data was analysed by the distance travelled in the inner segment versus outer segment of the 
arena (B). At 10.5 months, there was a significant difference between genotypes in the inner (C, 
ANOVA, F[3,69]=4.075, p=0.010) and outer (D, ANOVA F[3,69]=15.91, p<0.0001) portions of the arena. 
APP/PS1+Tau mice travelled significantly further in both the inner and outer arena compared to 
MAPTnull mice (* Tukey’s posthoc test p<0.01).  At 14.5 months, there were no significant differences 
between genotype and treatment in distance travelled in the inner arena (E). At 14.5 months of age, 
APP/PS1+Tau mice travel over 2 times farther in the outer portion of the arena (F) than other 
genotypes, a phenotype which recovers with dox treatment (2-way ANOVA genotype F[3,69]=19.548, 
p<0.0001; treatment F[1,69]=3.9990, p=0.0497, interaction F[2,69]=4.770, p=0.004. *, ** Tukey’s 
multiple comparisons tests p=0.002, p<0.0001). Graphs depict mean ± SEM. Individual points 
represent the mean value for each mouse. The dotted line in A indicates that a different cohort of 
mice was used at 3,6, 9 months of age and at 10.14 months of age. 
 
 
 
Figure S3 related to Figure 3: RT-PCR validation of RNA-seq results at 9 months and 14.5 months of 
age indicate that the upregulated genes GFAP (A), Trem2 (B), Cd180 (C), and Cd84 (D) increase 
between 9 and 14.5 months and that this is prevented by dox treatment.  The percentage area 
occupied by GFAP labelled astrocytes (cyan, E) and Iba1 labelled microglia (magenta E) was higher in 
14.5 month old mice in genotypes with plaques but did not change with tau transgene suppression 
(F, GFAP 2-way ANOVA effect of genotype F[3,31]=75.16, p<0.001, treatment F[1,31]=3.22, p=0.082; 
G, Iba1 2-qay ANOVA effect of genotype F[3.31]=9.05, p=0.0002, treatment F[1,31]2.48, p=0.13). 
Dox treatment significantly rescues transcriptional changes in Tau mice at 14.5 months (H) without 
affecting control mice (I). Dox treated control data correlate very closely with values from vehicle 
treated control animals (J). To visualise recovery of networks with dox treatment, the changes in 
APP/PS1+Tau vehicle treated mice compared to controls are shown for glutamate signalling (j) and 
complement  system (l) and dox treated APP/PS1+Tau mice compared to controls are shown in k and 
m.  Transcripts labelled in red are increased and those labelled in green are decreased.  Scale bar 
represents 40 m. 
  
 
Figure S4 related to Figures 3 and 4:  Tau suppression does not affect amyloid pathology.  Tau 
suppression did not change amyloid pathology in APP/PS1+Tau mice. In 14.5 month old mice, fibrillar 
plaques were measured with ThioS, total Aß with AW7 immunostaining, and oligomeric Aß halos were 
measured by subtracting the fibrillar cores from total Ab staining (a).  None of the amyloid plaque 
measurements was changed by doxycycline treatment (b-e).  APP mRNA levels (f) were increased by 
30% in APP/PS1+Tau mice, an effect which was ameliorated by dox treatment (2-way ANOVA 
genotype F[3,31]=153.5, p<0.0001, treatment F[1,31]=7.912, p=0.0084, interaction F[3,31]=3.468, 
p=0.0279, * post-hoc Tukey‘s test p<0.01). Soluble Aß42 ELISA on brain homogenates (g) showed a 
significant effect of genotype since mice without the human APP/PS1 transgene have low levels of Aß 
(2-way ANOVA effect of genotype F[3,26]=13.14, p<0.0001). There was a significant effect of dox 
treatment when all genotypes were considered (2-way ANOVA effect of treatment F[1,26]=6.11, 
p=0.02), however post-hoc analyses reveal that Aß42 levels were not changed in APP/PS1+Tau mice 
compared to APP/PS1 mice an neither APP/PS1+Tau nor APP/PS1 Aß42 levels were significantly 
reduced by dox treatment (Tukey’s multiple comparisons tests p>0.05). Scale bar represents 30 m.  
 
 
 Figure S5 related to Figure 4:  Tau suppression reduces post-synaptic accumulation of tau. To 
investigate post-synapse loss and synaptic proteins, array tomography ribbons from 14.5 month old 
mice were stained for postsynaptic terminals (green), human tau (red), and amyloid beta (AW7, cyan). 
Maximum intensity projections of 10 serial 70 nm sections are shown in a.  Three-dimensional 
reconstructions of 5 consecutive serial sections from processed image stacks of a APP/PS1+Tau mouse 
(b) demonstrate post-synaptic terminals positive for tau (arrows) or A (arrowheads). Quantification 
reveals significant post-synapse loss near plaques in APP/PS1 and APP/PS1+Tau mice which is not 
rescued by lowering tau levels with doxycycline (dox) treatment (c). The percentage of post-synapses 
positive for A is not different between APP/PS1 mice and APP/PS1+Tau mice, nor is it affected by dox 
treatment (d).   The percentage of post-synapses containing tau is significantly lowered by dox 
treatment in APP/PS1+Tau mice (e, * Mann-Whitney U test p=0.004). Data represent mean + SEM (c) 
and median + interquartile range (d-e). Scale bars represent 10 m in a, 1 m in b. 
 
Table S5 related to STAR methods - oligonucleotides 
Genotyping primers 
PSEN1dE9 forward primer: GGCTACCATTAAGTCAGTCAGCTTT  
PSEN1dE9 reverse primer: CCCACAGTCTCGGTATCTTCTG  
APPSwe forward primer: CCGACATGACTCAGGATATGAAGTT 
APPSwe reverse primer: CCGACATGACTCAGGATATGAAGTT 
CkTTA forward primer: TGCCAACAAGGTTTTTCACTAGAGA 
CkTTA reverse primer: CTCTTGATCTTCCAATACGCAACCTA 
MAPT forward primer: CTGCTCCAAGACCAAGAAGGA 
MAPT reverse primer: TGTGTATGTCCACCCCACTGA 
RNASeq validation QPCR primers 
Gapdh forward primer: GGGTGTGAACCACGAGAAAT 
Gapdh reverse primer: CCTTCCACAATGCCAAAGTT 
MAPT forward primer: CCCAATCACTGCCTATACCC  
MAPT reverse primer: CCACGAGAATGCGAAGGA 
Human mutant APP forward primer: CCGACATGACTCAGGATATGAAGTT 
Human mutant APP reverse primer:  CCTTTGTTTGAAACCCACATCTTCTG 
Trem2 forward primer: CTGGAACCGTCACCATCACTC 
Trem2 reverse primer: CGAAACTCGATGACTCCTCGG 
Gfap forward primer: GCAAAAGCACCAAAGAAGGGGA 
Gfap reverse primer: ACATGGTTCAGTCCCTTAGAGG 
Aldh1l1 forward primer: CATCCAGACCTTCCGATACTTC 
Aldh1l1 reverse primer: ACAATACCACAGACCCCAAC 
Cd180 forward primer: CCAAAGCCAACATCGGTTAGACAC 
Cd180 reverse primer: CAGAGACCCTCAAACACGGCAGG 
Cd84 forward primer: GCTGAAGTTACCATAACCCAGG 
Cd84 reverse primer: CAAAAGTAAATCCAAGGCCCCG 
 
 
